Phase III PROSPER trial of enzalutamide + ADT successful in nmCRPC

The Phase III PROSPER trial of enzalutamide + androgen deprivation therapy (ADT) versus a placebo + ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC) has apparently met its primary endpoint of improved metastasis-free survival. … READ MORE …

Update on STAMPEDE data on abiraterone + ADT in M0 patients with HSPC

Three months ago, James et al. presented the overall survival data from the most recently completed arm of the STAMPEDE trial at the annual meeting of the American Society of Clinical Oncology (ASCO). … READ MORE …

Differing chemotherapies and their effects in the treatment of mCRPC

The results of two recent, large clinical trials may have some impact on the clinical use of cabazitaxel (Jevtana) in the treatment of late-stage prostate cancer. … READ MORE …

The proposed, Finnish, ProScreen trial

A group of Finnish researchers have planned a new trial to investigate whether population-based screening for prostate cancer is justifiable if a mortality benefit can be proven with a substantial reduction in rates of over-treatment. … READ MORE …

Prostate cancer and treatment with immune checkpoint inhibitors

Immune checkpoint inhibitors include drugs like ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), and others that can have dramatic effects on the survival of some groups of patients with advanced forms of some cancers. … READ MORE …

The “right” ways to treat TxN1M0 disease today

Really sound guidance on “the best” way to treat men who are initially diagnosed with lymph node-positive (TxN1M0) prostate cancer — or are found to have such cancer at the time of first-line surgery — is not as readily available as one might like. … READ MORE …

Predicting outcomes on active surveillance for intermediate-risk patients

It is now clear that men who meet NCCN criteria for very low- and low-risk forms of prostate cancer are almost invariably good candidates for initial management on active surveillance (i.e., just monitoring as opposed to immediate treatment). … READ MORE …